IBI363 + platinum doublet chemotherapy

IBI363 + platinum doublet chemotherapy is an investigational combination immunotherapy and chemotherapy regimen being developed for the treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC). The regimen combines IBI363 (TAK-928), a first-in-class recombinant bispecific fusion protein consisting of an anti-programmed cell death protein 1 (PD-1) antibody fused to an engineered, interleukin-2 receptor alpha (IL-2Rα)-biased interleukin-2 (IL-2) variant, with standard platinum-based doublet chemotherapy (such as pemetrexed or paclitaxel combined with cisplatin or carboplatin). IBI363 simultaneously blocks the PD-1/PD-L1 inhibitory pathway and selectively activates the IL-2 pathway on tumor-specific T cells, while the chemotherapy component induces cytotoxic tumor cell death and promotes immunogenic cell death, potentially synergizing with the immunotherapy to overcome immune-cold or immunotherapy-resistant tumors. The combination is being co-developed globally by Innovent Biologics and Takeda.

Other names

IBI363 + PDCIBI363 + platinum doublet chemotherapyIBI363 + platinum-based doublet chemotherapyIBI363 plus PDCIBI-363 plus PDCIBI 363 plus PDCIBI363 plus platinum doublet chemotherapyIBI-363 plus platinum doublet chemotherapyIBI 363 plus platinum doublet chemotherapyIBI363 plus platinum-based doublet chemotherapyIBI-363 plus platinum-based doublet chemotherapyIBI 363 plus platinum-based doublet chemotherapyTAK-928 + PDCTAK-928 + platinum doublet chemotherapyTAK-928 + platinum-based doublet chemotherapyTAK-928 plus PDCTAK928 plus PDCTAK 928 plus PDCTAK-928 plus platinum doublet chemotherapyTAK928 plus platinum doublet chemotherapyTAK 928 plus platinum doublet chemotherapyTAK-928 plus platinum-based doublet chemotherapyTAK928 plus platinum-based doublet chemotherapyTAK 928 plus platinum-based doublet chemotherapyTAK928 + PDCTAK928 + platinum doublet chemotherapyTAK928 + platinum-based doublet chemotherapy